MX2009003645A - N-substituted-azacyclylamines as histamine-3 antagonists. - Google Patents

N-substituted-azacyclylamines as histamine-3 antagonists.

Info

Publication number
MX2009003645A
MX2009003645A MX2009003645A MX2009003645A MX2009003645A MX 2009003645 A MX2009003645 A MX 2009003645A MX 2009003645 A MX2009003645 A MX 2009003645A MX 2009003645 A MX2009003645 A MX 2009003645A MX 2009003645 A MX2009003645 A MX 2009003645A
Authority
MX
Mexico
Prior art keywords
histamine
azacyclylamines
antagonists
substituted
variables
Prior art date
Application number
MX2009003645A
Other languages
Spanish (es)
Inventor
Jonathan Laird Gross
William Ronald Solvibile
Albert Jean Robichaud
Marla Jean Williams
Ji-In Kim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009003645A publication Critical patent/MX2009003645A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: (I) wherein the variables are described in the specification.
MX2009003645A 2006-10-06 2007-10-05 N-substituted-azacyclylamines as histamine-3 antagonists. MX2009003645A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85014306P 2006-10-06 2006-10-06
PCT/US2007/021474 WO2008045371A2 (en) 2006-10-06 2007-10-05 N-substituted-azacyclylamines as histamine-3 antagonists

Publications (1)

Publication Number Publication Date
MX2009003645A true MX2009003645A (en) 2009-04-22

Family

ID=39166787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003645A MX2009003645A (en) 2006-10-06 2007-10-05 N-substituted-azacyclylamines as histamine-3 antagonists.

Country Status (13)

Country Link
US (1) US7935719B2 (en)
EP (1) EP2074088A2 (en)
JP (1) JP2010505851A (en)
CN (1) CN101583596A (en)
AR (1) AR063147A1 (en)
AU (1) AU2007307105A1 (en)
BR (1) BRPI0719950A2 (en)
CA (1) CA2665071A1 (en)
CL (1) CL2007002899A1 (en)
MX (1) MX2009003645A (en)
PE (1) PE20081152A1 (en)
TW (1) TW200831077A (en)
WO (1) WO2008045371A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530274A (en) * 2006-03-15 2009-08-27 ワイス N-substituted azacyclylamine compounds as histamine-3 antagonists
AU2007254232A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
PE20081152A1 (en) 2006-10-06 2008-08-10 Wyeth Corp N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS
PE20090720A1 (en) * 2007-05-24 2009-06-11 Wyeth Corp DERIVATIVES OF AZACICLYLBENZAMIDE AS ANTAGONISTS OF HISTAMINE-3
PE20090812A1 (en) 2007-07-16 2009-06-14 Wyeth Corp AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US8367679B2 (en) 2008-12-09 2013-02-05 Merck Sharp & Dohme Corp. Biaryl carboxamides
BRPI1011258A2 (en) * 2009-06-26 2016-03-22 Sanofi Sa fumarate salts, use thereof, pharmaceutical composition comprising them and processes for preparing said composition and 2- (cyclohexylmethyl) -n- {2 - [(2s) -1-methylporrolidin-2-difumarate monohydrate yl] ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN104447567B (en) * 2014-11-02 2016-06-29 湖南华腾制药有限公司 A kind of preparation method of 1 substituted benzimidazole derivant
JP2018526452A (en) 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ DYRK1A small molecule inhibitor and use thereof
EP3986886A2 (en) * 2019-06-19 2022-04-27 Grünenthal GmbH Substituted pyrrolidine amides v

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
DK0650476T3 (en) 1993-04-07 2002-07-22 Otsuka Pharma Co Ltd Peripheral vasodilating agent containing N-acylated 4-aminopiperidine derivatives as active ingredients
JPH08225535A (en) 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd Indazole derivative
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ES2210747T3 (en) 1997-05-01 2004-07-01 Eli Lilly And Company ANTITROMBOTIC AGENTS.
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
ES2325477T3 (en) 2000-03-31 2009-09-07 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. INDOLES REPLACED BY PHENYLL AS ANTAGONISTS OF HISTAMINE RECEIVER H3.
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
HN2002000156A (en) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE.
ATE447404T1 (en) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic SUBSTITUTED BENZAZOLES AND THEIR USE AS RAF-KINASE INHIBITORS
US7276505B2 (en) * 2003-03-14 2007-10-02 Medigene Limited Immunomodulating heterocyclic compounds
CN104193750B (en) * 2004-05-14 2018-04-27 千禧药品公司 Suppress mitotic Compounds and methods for by suppressing aurora kinase
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
DK1786790T3 (en) 2004-07-26 2009-07-20 Lilly Co Eli Oxazole derivatives such as histamine H3 receptor substances, preparation and therapeutic applications
ES2534605T3 (en) * 2004-08-23 2015-04-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
UY29149A1 (en) 2004-10-07 2006-05-31 Boehringer Ingelheim Int TIAZOLIL-DIHIDRO-INDAZOLES
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
WO2006078775A1 (en) * 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
JP2008537953A (en) * 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド Novel compounds useful for bradykinin B1 receptor antagonism
DE102005055515A1 (en) 2005-07-26 2007-02-01 Huf Hülsbeck & Fürst Gmbh & Co. Kg Sensor arrangement and method for detecting the resting of an operator body part on an actuating point of a motor vehicle closing device with a sensor-assisted evaluation of the output signal of a proximity sensor
JP2009530274A (en) 2006-03-15 2009-08-27 ワイス N-substituted azacyclylamine compounds as histamine-3 antagonists
JP2009531320A (en) * 2006-03-20 2009-09-03 グラクソ グループ リミテッド Compounds that potentiate AMPA receptors and their use in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (en) 2006-10-06 2008-08-10 Wyeth Corp N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS

Also Published As

Publication number Publication date
WO2008045371A2 (en) 2008-04-17
CN101583596A (en) 2009-11-18
US7935719B2 (en) 2011-05-03
CL2007002899A1 (en) 2008-01-11
AU2007307105A1 (en) 2008-04-17
AR063147A1 (en) 2008-12-30
WO2008045371A3 (en) 2008-06-19
US20080119458A1 (en) 2008-05-22
JP2010505851A (en) 2010-02-25
TW200831077A (en) 2008-08-01
EP2074088A2 (en) 2009-07-01
CA2665071A1 (en) 2008-04-17
PE20081152A1 (en) 2008-08-10
BRPI0719950A2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2009003645A (en) N-substituted-azacyclylamines as histamine-3 antagonists.
MX2010002899A (en) Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists.
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MX2010002760A (en) Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists.
IL243574B (en) Pharmaceutical composition for use in treating a disorder treatable by purine receptor blocking
BRPI0715893A2 (en) azetidine compound and use for the preparation of a medicament for the prevention or treatment of dysthymic or sleep disorders
DE602008005771D1 (en) DISUBSTITUTED ALKYL-8-AZABICYCLOÄ3.2.1ÜOKTAN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
MX2009005363A (en) Pyrimidines and their use as cxcr2 receptor antagonists.
CR10309A (en) "COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1"
MX2010002732A (en) F1f0-atpase inhibitors and related methods.
UA94639C2 (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
MX2009004822A (en) Phenylpropionamide compounds and the use thereof.
MX2009003316A (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators.
MX2009003981A (en) Calcium receptor modulating agents.
UA106873C2 (en) COMPOUNDS OF SUBSTITUTED DIAZEPANES AS ANXAGONES OF OREXIN RECEPTORS
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
MX2009006170A (en) Compounds and compositions as kinase inhibitors.
MX2008013196A (en) 5-amido-2-carboxamide indoles.
IL193479A0 (en) Modulators of muscarinic receptors
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MY150600A (en) Use of opioid antagonists for treating urinary retention
ATE466854T1 (en) 1H-INDOLE-6-YLPIPERAZINE-1-YLMETHANONE DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS
MX2011010782A (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders.
MX368459B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal